OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Vistagen Therapeutics OCF Yield % Related Terms
Vistagen Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Vistagen Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VTGN vs PSTV, KYNB, TVGN: OCF Yield % Comparison
For the Biotechnology subindustry, Vistagen Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vistagen Therapeutics (MEX:VTGN) has a OCF Yield % of -230.64 as of Jun. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Vistagen Therapeutics and its competitors. According to the industry distribution chart, Vistagen Therapeutics ranks #1359 out of 1416 companies in the Biotechnology industry, placing it in the top 96%.
Is Vistagen Therapeutics' OCF Yield % too high?
Vistagen Therapeutics' current OCF Yield % is -230.64. Based on the distribution chart, Vistagen Therapeutics ranks #1359 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vistagen Therapeutics has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' OCF Yield % compare to PSTV and KYNB?
According to the Biotechnology industry distribution chart, Vistagen Therapeutics ranks #1359 out of 1416 companies for OCF Yield %. This places Vistagen Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current OCF Yield % is -230.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (MEX:VTGN) has a current OCF Yield % of -230.64. The stock's GF Value™ is MXN33.38, compared to a current price of MXN10.65 — trading 68.1% below its estimated fair value. The current OCF Yield % is -230.64. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Vistagen Therapeutics (MEX:VTGN), the current OCF Yield % is -230.64 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistagen Therapeutics (MEX:VTGN) Overvalued in 2026?
Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued.
The current stock price of MXN10.65 is trading 68.1% below its estimated GF Value™ of MXN33.38.
Key valuation signals for MEX:VTGN:
OCF Yield %: -230.64
GF Value™: MXN33.38 vs. price of MXN10.65 (68.1% below fair value)
No single metric tells the full story. See the MEX:VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score
Get the complete analysis for MEX:VTGN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VTGN has been successfully added to your 
